Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marianne Weulersse"'
Autor:
Stanislas Goriely, Marie-Véronique Joubert, Tobias Bald, Mark J. Smyth, Ludovic Martinet, Elena Morandi, Loïc Dupré, Laure Buisson, Nadège Carrié, Marianne Weulersse, Guillaume Gaud, Marie Le Moine, Thomas Gossye, Anne Dejean, Hervé Avet-Loiseau, Ashmitha Sundarrajan, Assia Asrir, Andrea C. Pichler, Michaël Pérès, Abdelhadi Saoudi, Alejandra Martinez, Julien Mazieres, Sahar Kassem, Elisa Brauns, Els Verhoeyen, Indrajit Das, Sabrina Maheo, Matthias Braun, Vera Pancaldi, Clara Maria Scarlata, Marine Cuisinier, Maha Ayyoub, Laura Do Souto, Lea Lemaitre, Arantxa Agesta, Camille Guillerey
Publikováno v:
Immunity, 53 (4
Immunity
Immunity, Elsevier, 2020, 53 (4), pp.824-839.e10. ⟨10.1016/j.immuni.2020.09.006⟩
Immunity, 2020, 53 (4), pp.824-839.e10. ⟨10.1016/j.immuni.2020.09.006⟩
Immunity
Immunity, Elsevier, 2020, 53 (4), pp.824-839.e10. ⟨10.1016/j.immuni.2020.09.006⟩
Immunity, 2020, 53 (4), pp.824-839.e10. ⟨10.1016/j.immuni.2020.09.006⟩
Through complementary approaches, involving cancer patients’ samples and relevant mouse tumor models, Weulersse et al. reveal that CD8 T cells in the tumor microenvironment lose expression of the activating receptor CD226 (DNAM-1) in a manner that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dfe5be6f45852b02f2ba60ac27610fa
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/316003
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/316003
Autor:
Hervé Avet-Loiseau, Mark J. Smyth, Kyohei Nakamura, Geoffrey R. Hill, Sophie Krumeich, Sahar Kassem, Nadège Carrié, Kimberley Stannard, William C. Dougall, Tricia Teo, Camille Guillerey, Marine Cuisinier, Marianne Weulersse, Heidi Harjunpää, Michele W.L. Teng, Yuan Yu, Ludovic Martinet, Simone A. Minnie, Kim Miles
Publikováno v:
Blood. 132:1689-1694
Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven effective as single agent in this disease. T-cell immunoglobulin and ITIM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c30854396fb6a96ea399fb88dacb59a1
https://doi.org/10.1182/blood-2018-01-825265
https://doi.org/10.1182/blood-2018-01-825265
Autor:
Camille, Guillerey, Heidi, Harjunpää, Nadège, Carrié, Sahar, Kassem, Tricia, Teo, Kim, Miles, Sophie, Krumeich, Marianne, Weulersse, Marine, Cuisinier, Kimberley, Stannard, Yuan, Yu, Simone A, Minnie, Geoffrey R, Hill, William C, Dougall, Hervé, Avet-Loiseau, Michele W L, Teng, Kyohei, Nakamura, Ludovic, Martinet, Mark J, Smyth
Publikováno v:
Blood. 132(16)
Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven effective as single agent in this disease. T-cell immunoglobulin and ITIM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e864d73ffd88e0398dec61a56160c2d7
https://pubmed.ncbi.nlm.nih.gov/30337318
https://pubmed.ncbi.nlm.nih.gov/30337318